« Novel drug delivery system to overcome barriers | AGS Therapeutics to Present at BIO CEO & Investor Conference NYC », Paris, FR, February 6, 2023.

AGS Therapeutics to Present at BIO CEO & Investor Conference NYC [ Company developing novel drug delivery system to overcome barriers ]

PARIS, FRANCE, February 6, 2023-- AGS Therapeutics is a biotech company developing innovative biomedicines based on extracellular vesicles from microalgae (MEV), a new kind of safe, targeted, and highly versatile delivery system for therapeutic molecules from natural and synthetic biology designed to address a wide range of illnesses will make a virtual company presentation at the BIO CEO & Investor Conference at the Marriot Marquis in New York City.

Dr. Manuel Vega, CEO and Co-founder will update investors on the AGS technology for a novel drug delivery system. 

Widespread use of today’s innovative biologics - RNA, DNA, proteins, gene editing complexes, and gene expression plasmids - for the treatment of human diseases remains elusive due, in part, to our collective inability to deliver therapeutic doses to the right target in the body without affecting other organs or tissues. The lack of an effective drug delivery system (DDS), which can overcome the human body’s natural barriers, has been a significant bottleneck in unleashing the power of the most advanced biologics as effective biomedicines for patients.

About AGS Therapeutics

AGS Therapeutics, based in Paris, France, is a biotech company developing biomedicines based on extracellular vesicles from microalgae (MEV) as a safe, targeted and highly versatile delivery system for innovative biologics, such as mRNA, siRNA, DNA, and proteins for a broad range of human diseases. AGS-M, the company’s subsidiary and a contract development and manufacturing organization, will produce the MEV needed to support preclinical and clinical development of MEV-based product pipelines from AGS and from pharmaceutical companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable. For more information visit www.ags-tx.com and www.ags-m.com.

Contact:

Dan Eramian

Opus Biotech Communications

425-306-8716

All Press Releases
« AGS Therapeutics Strengthens its Patent Portfolio on Microalgae Extracellular Vesicles (MEVs) with an International Application on the use of MEVs to deliver biological agents to the brain by the intranasal route of administration », Paris, May 7, 2024.
« AGS Therapeutics Strengthens its Patent Portfolio on Microalgae Extracellular Vesicles (MEV) with an International Patent Application on MEVs from Genetically Modified Microalgae Containing Endogenously-Loaded Payloads », Paris, FR, January 17, 2024.
« AGS Therapeutics Named among BWM’s 20 Most Innovative Companies to Watch in 2023 », London, UK, August 2023.
« AGS Therapeutics Strengthens its Patent Portfolio on Microalgae Extracelluar Vesicles (MEV) with an International Patent Application on Biodistribution and Uses of MEVs as Delivery System to Reach Difficult to Access Tissues », Paris, FR, August 7, 2023.
« AGS Therapeutics Announces Move to Spartners, the already Prestigious Accelerator within the Paris-Saclay Life Sciences Hub », Paris, FR, May 30, 2023.
« AGS Therapeutics Strenghtens its Patent Portfolio on Microalgae Extracelluar Vesicles (MEV) with an  International Patent Application on Preparation and Uses of MEVs as a Universal Drug Delivery System », Paris, FR, Mai 8, 2023.
« AGS Therapeutics Unveils Ambitious R&D Pipeline, Showcasing the Potential of its Universal Delivery System for Novel Therapeutics », Paris, FR, April 4, 2023.
Featured
No items found.